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Abstract 
OBJECTIVE 
Long-term administration of intravenous bisphosphonates like pamidronate is associated with jaw 
osteonecrosis but axial and appendicular bones are unaffected. Pathogenesis of bisphosphonate-
associated jaw osteonecrosis may relate to skeletal-site specific effects of bisphosphonates on 
osteogenic differentiation of bone marrow stromal cells (BMSCs) of orofacial and axial/appendicular 
bones. This study evaluated and compared skeletal site-specific osteogenic response of mandible 
(orofacial bone) and iliac crest (axial bone) human BMSCs to pamidronate. 
MATERIALS AND METHODS 
Mandible and iliac crest BMSCs from six normal healthy volunteers were established in culture and tested 
with pamidronate to evaluate and compare cell survival, osteogenic marker alkaline phosphatase, 
osteoclast differentiation in co-cultures with CD34+ hematopoietic stem cells, gene expression of 
receptor activator of NFκB ligand (RANKL) and osteoprotegerin, and in vivo bone regeneration. 
BRESULTS 
Mandible BMSCs were more susceptible to pamidronate than iliac crest BMSCs based on decreased cell 
survival, lower alkaline phosphatase production and structurally less organized in vivo bone regeneration. 
Pamidronate promoted higher RANKL gene expression and osteoclast recruitment by mandible BMSCs. 
CONCLUSION 
Mandible and iliac crest BMSC survival and osteogenic differentiation are disparately affected by 
pamidronate to favor dysregulated mandible bone homeostasis. 
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Abstract
OBJECTIVE—Long-term administration of intravenous bisphosphonates like pamidronate is
associated with jaw osteonecrosis but axial and appendicular bones are unaffected. Pathogenesis of
bisphosphonate-associated jaw osteonecrosis may relate to skeletal-site specific effects of
bisphosphonates on osteogenic differentiation of bone marrow stromal cells (BMSCs) of orofacial
and axial/appendicular bones. This study evaluated and compared skeletal site-specific osteogenic
response of mandible (orofacial bone) and iliac crest (axial bone) human BMSCs to pamidronate.
MATERIALS AND METHODS—Mandible and iliac crest BMSCs from six normal healthy
volunteers were established in culture and tested with pamidronate to evaluate and compare cell
survival, osteogenic marker alkaline phosphatase, osteoclast differentiation in co-cultures with
CD34+ hematopoietic stem cells, gene expression of receptor activator of NFκB ligand (RANKL)
and osteoprotegerin, and in vivo bone regeneration.
BRESULTS—Mandible BMSCs were more susceptible to pamidronate than iliac crest BMSCs
based on decreased cell survival, lower alkaline phosphatase production and structurally less
organized in vivo bone regeneration. Pamidronate promoted higher RANKL gene expression and
osteoclast recruitment by mandible BMSCs.
CONCLUSION—Mandible and iliac crest BMSC survival and osteogenic differentiation are
disparately affected by pamidronate to favor dysregulated mandible bone homeostasis.
Keywords
Bisphosphonate; Osteonecrosis; Jaw; Stem cells; Bone
Introduction
Two nitrogen-containing bisphosphonates, pamidronate (Aredia ™) and zoledronic acid
(Zometa™) used to treat bone-associated cancer metastasis cause osteonecrosis of the jaws.
Bisphosphonate-associated jaw osteonecrosis (BJON) is characterized by tissue dehiscence,
chronic bone devitalization, hypocellularity, lytic radiographic features and it is usually
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refractory to therapy (Marx et al., 2005; Migliorati et al., 2005; Migliorati et al., 2006; Ruggiero
et al., 2004). BJON tends to occur in craniofacial bones (maxilla, mandible and an isolated
case in external auditory canal (Polizzotto et al., 2006) indicating that it favors craniofacial
bones over other skeletal sites. Why this occurs is still unclear. While bisphosphonates are
widely used to treat osteoporosis, pamidronate and zoledronic acid are administered
intravenously at high doses to treat hypercalcemia of malignancy, Paget’s disease, and
osteolytic lesions of multiple myeloma and cancer metastasis.
Bisphosphonates are pyrophosphates analogues with carbon replacing oxygen in the
pyrophosphate bond. They have high affinity for hydroxyapatite and remain unmetabolized
for long periods of time because of their resistance to enzymatic hydrolysis, heat and most
chemicals. In addition, bisphosphonates prevent hydroxyapatite crystal formation, aggregation
and dissolution (Fleisch, 2000). Bisphosphonates directly inhibit osteoclast function when
internalized during bone resorption (Russell, 2006). Nitrogen-containing bisphosphonates like
pamidronate inhibit farnesyl pyrophosphate synthase, an enzyme responsible for the formation
of farnesyl pyrophosphate (Roelofs et al., 2006) Inhibition of this pathway results in disruption
of protein prenylation, which is vital for the function of essential signaling proteins
(GTPases).The inhibitory action of bisphosphonates on farnesyl pyrophosphate synthase, and
consequently osteoclasts, as well as high binding affinities to hydroxyapatite both contribute
to their high in vivo antiresorptive potency and long duration of action (Michael J. Rogers,
2000; Russell, 2006). Bisphosphonates also inhibit osteoclastic activity indirectly through
osteoblasts. Interaction of osteoblast cell surface receptor activator of NFκB ligand (RANKL)
with RANK on hematopoietic osteoclast precursor cells enhances osteoclast recruitment and
activation. However osteoblasts also secrete osteoprotegerin (OPG), a soluble receptor that
competes with RANKL for RANK to inhibit osteoclast recruitment and control osteoblast-
osteoclast balance (Kostenuik, 2005; Lacey et al., 1998). RANKL is also expressed on the
surface of bone marrow stromal cells (BMSCs), a putative population of postnatal stem cells
within the bone marrow organ that can differentiate into multiple cell types including pre-
osteoblasts and osteoblasts. Thus BMSCs indirectly modulate osteoblast-osteoclast balance.
It is unclear why BJON is limited to the craniofacial bones. One possibility is the skeletal site-
specific osteogenic properties of BMSCs in maxilla and mandible (orofacial bones) compared
with those in axial and appendicular bone based on their different embryological origins
(Akintoye et al., 2006). Maxilla, mandible including alveolar bone, dentine, pulp and
periodontal ligament are formed exclusively by neural crest cells while axial and appendicular
bones develop from mesoderm (Chai et al., 2000; Charbord et al., 1996). In same individuals,
orofacial BMSCs (from maxilla and mandible) have more proliferative and osteogenic
capacities than iliac crest BMSCs (Akintoye et al., 2006). Since BJON is jaw-specific, and
orofacial BMSCs are developmentally and phenotypically different from those of iliac crest,
we hypothesized that pamidronate modulates in vitro and in vivo osteogenic differentiation of
human BMSCs in a skeletal site-specific pattern; a property that may relate to jaw-specific
pathogenesis of BJON.
Material and Methods
Subjects and cell culture
After written informed consent, 6 healthy normal, unmedicated volunteers who needed 3rd
molar surgery were enrolled in an Institutional Review Board-approved protocol at the
University of Pennsylvania, Philadelphia PA. Sample size was based on previous studies that
showed 4 subjects were sufficient to demonstrate skeletal site-specific differences at a power
of 0.8 and α level of 0.05 (Akintoye et al., 2006; von Knoch et al., 2005). During 3rd molar
surgery, trabecular bone with marrow from mandible (orofacial skeletal site) and bone marrow
aspirate from iliac crest (axial skeletal site) were obtained simultaneously from each individual.
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From the two skeletal sites, nucleated cells were isolated. Primary culture of human BMSCs
were established with growth medium of α-modified minimum essential medium (α-MEM)
supplemented with 20% fetal bovine serum (FBS) (Equitech Bio Inc, Kerville TX), 100 U/ml
penicillin, 100 mg/ml streptomycin sulfate and 2 mM glutamine (BioSource International
Camarillo CA), incubated at 37 °C in a humidified atmosphere of 5% CO2 and air as previously
described (Akintoye et al., 2006).
Dose response and cell proliferation
Dose response of each BMSC type to pamidronate was compared by sub-culturing early
passage (passage 2) cells in triplicate wells of 24-well plates at a seeding density of 104 cells/
cm2 in growth medium. After 24 hours, growth medium was replaced with fresh ‘modified
growth medium’ in which FBS was replaced with 1% ITS+ premix (BD Biosciences, San Jose
CA) and different doses of pamidronate (Novartis Pharmaceuticals, East Hanover, NJ) at 0
(control), 2.5, 5, 10 and 25 μg/ml. After 4 days exposure to pamidronate, metabolically active
viable cells were assessed using colorimetric WST-1 cell proliferation assay (Roche Applied
Science, Indianapolis, IN). In separate plates of parallel experiments, cells were stained with
2 μg/ml DAPI to assess viable BMSCs. Subsequently, 2.5 μg/ml of pamidronate was tested in
experiments described below.
Alkaline phosphatase assay
Early passage (passage 2) BMSCs seeded at 104 cells/cm2 were cultured as above in 24-well
plates for 4 days before switching to modified growth medium containing 2.5 μg/ml of
pamidronate for another 4 days. Alkaline phosphatase activity was assessed on day 8 using the
4-nitrophenyl phosphate reaction as previously described (Akintoye et al., 2006). Alkaline
phosphatase activity was normalized to the total protein content of cell lysate. To assess
possible recovery from pamidronate effect, pamidronate-treated cells in separate parallel plates
were replenished with growth medium without pamidronate on day 9 for additional four days
before assaying for alkaline phosphatase on day 12.
Co-culture of human hematopoietic stem cells (HSCs) and bone marrow stromal cells
Human CD34+ HSCs (Cambrex Corporation, East Rutherford, NJ) were added at 5 × 104 cells/
cm2 to triplicate wells of 24-well plates containing monolayer of BMSCs cultured with 2.5
μg/ml pamidronate-containing modified medium. The co-culture was maintained at 37°C, in
a humidified atmosphere of 5% CO2 and air for 4 weeks. Half of the culture medium was
replaced with fresh modified medium containing pamidronate at 3-day intervals.
Tartrate-resistant acid phosphatase (TRAP) staining
After 4 weeks of BMSC and HSC co-culture, modified growth medium was removed, adherent
cells were rinsed with PBS pre-warmed to 37°C, fixed with 60% acetone in citrate buffer (pH
5.4) for 1 minute followed by two rinses with warm PBS. Cells were stained for 30 minutes at
37°C with TRAP staining solution (pH 5.0) consisting of 0.05 M acetate buffer, 0.03 M sodium
tartrate, 1 mg/ml naphtol AS-MX disodium phosphate, 0.1% Triton X-100 and 0.3 mg/ml Fast
Red Violet LB (Mbalaviele et al., 1999). Red staining multinucleated cells with 3 or more
nuclei were counted as TRAP+ osteoclast-like cells under a bright field microscope.
Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)
Early passage mandible and iliac crest BMSCs were cultured at 104 cells/cm2 in 6-well plates
for 24 hours before switching to modified medium containing 2.5 μg/ml pamidronate. Total
RNA was isolated from sub-confluent cells using TRIzol® reagent (Invitrogen Life
Technologies, Carlsbad, California) and first strand cDNA was prepared with First Strand
SuperScript™ Double-Stranded cDNA Synthesis Kit (Invitrogen Life Technologies, Carlsbad,
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California) using an oligo-dT primer. 2 μl of first strand cDNA was added to a total volume
of 50 μl PCR buffer containing: 1.5 mM MgCl2, 200 μM dNTP, 2.5U Taq DNA polymerase
(Promega, Madison, WI) and 200 nM of each primer set for RANKL (GenBank accession #
AB064269.1; forward, 5′-TATGATGGAAGGTTCGTGGCT-3′; reverse, 5′-
ATGTTAGAGATCTTGGCCCAG-3′), OPG (GenBank accession # AF134187; forward, 5′-
CTT GCC CTG ACC ACT ACT-3′; reverse, 5′-TTG CCG TTT TAT CCT CTC-3′) and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH, GenBank accession # M33197;
forward, 5′-AGCCGCATCTTCTTTTGCGTC-3′; reverse, 5′-
TCATATTTGGCAGGTTTTTCT-3′) as internal control. The PCR reaction was carried out in
a Perkin Elmer thermal cycler (Perkin Elmer, Boston MA) at 94 °C for 2 minutes for 1 cycle,
then 94 °C (1 minute), 55 °C (1 minute), 72 °C (1 minute) for 35 cycles and final extension at
72 °C (10 minutes). 15 μl of the amplified products were separated on 2% agarose gel, stained
with ethidium bromide and visualized with Kodak ImageStation 440 (Eastman Kodak,
Rochester, NY).
Bone Regeneration
Bone forming ability of pamidronate treated cells was assessed in vivo by transplantation into
the subcutis of 8 week-old immunocompromised nude female mice (NIH-III-nu, Charles River
Laboratories, Wilmington, MA) following University of Pennsylvania-approved animal
protocol. Using both control and pamidronate-treated BMSCs, 2 × 104 cells attached to 40 mg
spheroidal hydroxyapatite/tricalcium phosphate (particle size 0.5-1.0 mm, Zimmer, Warsaw
IN) were transplanted aseptically into separate subcutaneous pockets (Kuznetsov et al.,
1997). Transplants were harvested at 6 weeks, fixed with 4% paraformaldehyde, decalcified
in 10% EDTA (pH 8.0) and embedded in paraffin. Hematoxylin/eosin-stained 5 μm sections
were evaluated under a brightfield microscope. Bone formation was quantified semi-
quantitatively using a previously described and validated bone scoring method that ranged
from 0 (no bone evident within the transplant), 1 (minimal bone evident [1 trabecula]), 2 (weak
bone formation occupying only a small portion of the transplant), 3 (moderate bone formation
occupying a significant portion but less than 50% of the transplant) and 4 (abundant bone
formation, occupying more than 50% of the transplant +/− hematopoiesis) (Mankani et al.,
2001). To establish human origin of bone within transplants, unstained sections were
immunoreacted with rabbit anti-human osteopontin (OPN) polyclonal antibody (Cat # 499265,
EMD Biosciences, San Diego, CA) followed by enzymatic staining with broad-spectrum
immunoperoxidase AEC kit (Zymed Laboratories, San Francisco, CA) (Denhardt and Noda,
1998).
Statistical Analysis
Results of at least three experiments from all samples were expressed as mean ± standard
deviation (SD). Effects of pamidronate on the two cell types were compared either directly or
as fold-change over untreated cells. Data analysis was by one-way analysis of variance
(ANOVA) followed by post hoc comparisons with the Student’s two-tailed t test. Differences
were considered significant at P < 0.05.
Results
Pamidronate reduced mandible BMSCs proliferation in a dose-dependent fashion; however,
iliac crest BMSCs proliferation initially increased at 2.5 μg/ml pamidronate before a dose-
dependent decrease (Figure 1a). While 2.5 μg/ml dose of pamidronate was sub-lethal to both
cell types (Figures 1a and 1b), it significantly increased alkaline phosphatase levels in iliac
crest BMSCs with only minor effects on mandible cells (difference significant at p < 0.05),
(Figure 1c). These suggest that, iliac crest BMSCs responded to sub-lethal dose of pamidronate
with increased alkaline phosphatase production (osteogenic differentiation) and little effect on
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cell numbers, while mandible BMSCs responded with little increase in alkaline phosphatase
and reduced cell numbers (Figures 1a and 1c). After pamidronate-treated cells were re-
introduced to normal growth medium without pamidronate, mandible BMSCs recovered from
the effect of pamidronate by producing higher level of alkaline phosphatase (Figure 1c), but
iliac crest BMSCs did not show the same degree of recovery. Ability of osteoprogenitor cells
to increase osteoclast formation is a major mechanism by which bone-forming cells promote
bone resorption, therefore both mandible and iliac crest BMSCs induced osteoclast-like cell
aggregates when co-cultured with CD34+ HSCs in growth medium without pamidronate
(Figures 2a). After addition of pamidronate to the BMSCs-HSC co-culture, the number of
osteoclast aggregates was relatively more suppressed in iliac crest than in mandible co-cultures
(Figure 2b) but this difference was not statistically significant. RT-PCR analyses of RANKL
mRNA levels (Figure 2c) showed that pamidronate increased RANKL expression in mandible
BMSCs but not in iliac crest BMSCs. These data provide additional evidence that 2.5 μg/ml
pamidronate acted on mandible BMSCs to promote osteoclast differentiation and RANKL
gene expression but did not have the same effect on iliac crest BMSCs. OPG mRNA levels
between the two cell types were unchanged.
All pamidronate-treated BMSCs transplants formed ectopic bone, with more histologically
observable bone produced by mandible BMSCs (Figure 3b) than iliac crest BMSCs (Figure
3a), but bone laid down by pamidronate-pretreated mandible BMSCs appeared less organized
with more hypocellular osteoid-like regions lacking bone-lining cells (Figure 3d) while iliac
crest BMSCs formed a fibro-cellular bone matrix with cell-lined surface. Row of lining cells
were visible in transplants of untreated control BMSCs (Figures 3a and 3b) and treated iliac
crest cells (Figure 3c) but not in bone formed by pamidronate-treated mandible BMSCs (Figure
3d). The ectopic bone was a product of transplanted human BMSCs because bone in the
transplants was immunoreactive with rabbit anti-human OPN (Figure 3e). Semi-quantitative
assessment of bone formed by control and pamidronate-treated BMSCs showed pamidronate
enhanced in vivo bone formation in both control and pamidronate-treated cells (Figure 3f); an
indication that pre-treatment of BMSCs with pamidronate did not impair bone-forming ability
of either cell type when subsequently transplanted into a pamidronate-free host.
Discussion
Pamidronate is one of two intravenously administered bisphosphonates highly associated with
BJON that prompted several alerts to patients and clinicians (Greenberg, 2004; MedWatch,
2005; Migliorati, 2005; Migliorati et al., 2005; Ruggiero et al., 2004; Woo et al., 2006).
Although underlying pathogenesis remains unknown, results presented here indicate
pamidronate affected cell survival and osteogenic properties of mandible BMSCs differently
from those of iliac crest BMSCs. The pamidronate dose (2.5 μg/ml) tested was sub-lethal to
BMSCs, so that actively proliferating and viable cells were compared. This dose was also
therapeutically relevant because it lies within 0.73 - 2.61 μg/ml, the range of maximum serum
concentration 4 hours after pamidronate infusion (U.S. Package Insert, Novartis
Pharmaceuticals, East Hanover, NJ). BMSCs usually exhibit osteogenic properties whether
cultured in osteogenic or non-osteogenic medium, and superior osteoblastic differentiation by
mandible BMSCs over iliac crest BMSCs has been previously described (Akintoye et al.,
2006). In this study, BMSCs were tested under serum-free, non-osteogenic conditions to
minimize confounding variables since st culture media contain serum and glucocorticoids.
Compared with iliac crest, mandible BMSCs were less osteogenically responsive to
pamidronate based on alkaline phosphatase level, but they promoted osteoclast differentiation
of HSCs more than iliac crest BMSCs. The more marked osteogenic response of iliac crest
BMSCs to pamidronate is consistent with earlier reports that demonstrated increased
proliferation and osteogenic differentiation of bone marrow stromal cell lines (Nishida et al.,
2005) and iliac crest-derived BMSCs from 4 patients (von Knoch et al., 2005), but BMSCs
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from orofacial skeletal sites were not evaluated. Interestingly, mandible BMSCs showed better
recovery from pamidronate effect by producing more alkaline phosphatase than iliac crest cells
after they were re-cultured in growth medium without pamidronate (Figure 1c). Also, the
marked differences in RANKL mRNA transcripts and osteoclast aggregates induced by
mandible BMSCs (Figure 2b) were noteworthy because osteoclastogenesis in the co-culture
system was independent of added growth factors or cytokines. It is likely that mandible BMSCs
promoted osteoclast differentiation more than iliac crest BMSCs by expressing higher levels
of RANKL to activate RANK on osteoclast progenitors (Figure 2c). Although in vivo bone
formed by pamidronate-treated mandible BMSCs appeared less organized structurally (Figure
3d), pamidronate did not disrupt the relatively higher in vivo bone regenerative capacity of
mandible BMSCs (Figure 3f). A higher dose or continuous exposure to pamidronate may be
needed to demonstrate more site-specific in vivo osteogenic differences. Despite equal cell
plating density, control (untreated) mandible BMSCs have consistently demonstrated higher
proliferative capacity than iliac crest BMSCs (Akintoye et al., 2006); this may account for their
susceptibility to pamidronate since highly proliferating cells easily succumb to external
chemical and physical insults (Baran, 1996; Hayflick and Moorhead, 1961). The recovery
effect demonstrated in vitro by BMSCs in this study is noteworthy because transplanted
pamidronate-treated mandible BMSCs also recovered to form appreciable ectopic bone in host
tissue. Comparatively, the reduced cell proliferation and osteogenic differentiation coupled
with enhanced RANKL expression and osteoclastogenesis by mandible BMSCs favor
disruption of bone homeostasis in the mandible more than iliac crest.
It has been proposed that bisphosphonates effects may be concentrated in the jaws because of
higher blood supply and bone turnover than other bones due to constant daily activity, presence
of teeth and periodontal ligament (Marx et al., 2005). These make jaw bones more susceptible
to the anti-angiogenic actions of bisphosphonates (Fournier et al., 2002; Santini et al., 2002;
Watts et al., 1990) and dysregulated osteoblast-osteoclast equilibrium. The average lifespan
of osteoblast is 3 months compared to 2 weeks for osteoclasts (Manolagas, 1999), but both
function together in the same basic multicellular unit (BMU) during bone turnover to maintain
equilibrium. It is possible that BMU balance may be disrupted in mandible by pamidronate
suppression of BMSCs osteoblastic differentiation while enhancing osteoclast differentiation
and recruitment. Inadequate number of viable osteoblasts in the BMU coupled with constant
forces of jaw motion, speech and teeth occlusion will make bisphosphonate-compromised jaw
bones susceptible to microfractures. Subsequent tracking of oral microbes from oral cavity
through periodontal tissues can lead to subclinical infections and tissue necrosis that may
eventually cause BJON. Clinically, it is possible that a combination of bisphosphonate-
associated cellular stress on maxilla and mandible BMSCs due to long-term use, as well as
cancer related co-morbid factors, uncoupling of osteoblast-osteoclast equilibrium, reduced
vasculature, bone microfractures and tracking of oral microbes through the periodontium may
act in concert to produce a ‘bandwagon effect’ that lowers susceptibility threshold in favor
BJON (Sarin et al., 2007). Furthermore, paucity of bone lining cells at sites where pamidronate-
treated mandible BMSCs formed ectopic bone suggests that future bone repair might be
impaired.
There are limitations of the present study. The sample size of 6 is small, although power analysis
indicates sample size of 4 will show a difference between mandible and iliac crest BMSCs. It
is necessary to reconfirm these results in a larger population especially individuals taking
bisphosphonates. Also, BMSCs from multiple craniofacial, axial and appendicular skeletal
sites need to be compared and tested with several bisphosphonate formulations to conclusively
define skeletal site-specificity of BJON. The BMSCs were cultured in pamidronate for only 4
days whereas patients usually take bisphosphonates for months and years to control skeletal
lesions. Clinically, there are other co-morbid factors that may promote BJON, because cancer
patients on bisphosphonates are usually taking multiple medications including chemotherapy
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(Migliorati et al., 2006; Woo et al., 2006). While defining the details of pamidronate effect on
orofacial BMSCs will require further examination, it seems likely that site-specificity of BJON
may be attributed to skeletal-site specific osteogenic differentiation of human BMSCs and
osteoclast population.
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Figure 1.
Dose response of mandible and iliac crest bone marrow stromal cells to pamidronate and in
vitro osteogenic response. Surviving number of mandible and iliac crest BMSCs after 4 days
in medium containing increasing doses of pamidronate show a decrease in number of mandible
BMSCs starting from 2.5 μg/ml pamidronate, while cell numbers of iliac crest BMSCs were
not significantly affected by pamidronate until the concentration exceeded 5 μg/ml (a). Dose-
dependent decrease in cell survival is further demonstrated by a representative DAPI staining
of viable mandible BMSCs after 4 days in culture (b). (A similar pattern was displayed by iliac
crest BMSCs). 2.5 μg/ml pamidronate increased alkaline phosphatase response of iliac crest
BMSCs more than mandible BMSCs (* p< 0.03) which indicate that mandible BMSCs are
comparatively less responsive to pamidronate. After replenishing the culture with growth
medium without pamidronate for another 4 days, mandible BMSCs responded with enhanced
alkaline phosphatase production than iliac crest BMSCs (not significant at p< 0.05) that may
indicate a relatively better recovery capacity of mandible BMSCs to short-term exposure to
pamidronate (c). (Data presented is mean of n = 6 subjects).
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Figure 2.
Effect of sub-lethal dose of pamidronate on BMSCs-promoted osteoclast differentiation.
Mandible and iliac crest BMSCs co-cultured with CD34+ human HSCs for 4 weeks induced
osteoclast-like cells that were positive for tartrate-resistant acid phosphatase. Representative
samples are shown at low and high magnifications (a). Pamidronate-treated mandible BMSC-
HSC co-culture retained higher osteoclast promoting ability than iliac crest BMSCs based on
higher number of CD34+ HSCs that differentiated to osteoclasts (data presented is mean of n
= 6 subjects) (b). This is consistent with reverse transcriptase PCR results presented in the
representative ethidium bromide-stained agarose gels (c). Note the undetectable expression of
receptor activator of NFκB ligand (RANKL) in control cells (lanes 1 and 3; top panel). After
pamidronate treatment, there was marked expression of RANKL by mandible BMSCs (lane
3; middle panel) that still remained relatively undetectable in iliac crest cells (lane 1; middle
panel). Osteoprotegerin (OPG) level was not different between the two cell types in both control
and pamidronate-treated cells (lanes 2 and 4; top and middle panels). (Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) was used as an internal control; lower panel).
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Figure 3.
In vivo bone formation by pamidronate-treated mandible and iliac crest BMSCs Hematoxylin/
eosin-stained sections of bone formed by transplanted control (a and b) and pamidronate-
treated (c and d) BMSCs demonstrated that mandible BMSCs (b and d) formed more
histologically observable bone than iliac crest BMSCs (a and c) as previously reported
(Akintoye et al., 2006). Note distinct osteoblastic rimming indicative of bone lining cells in
mandible control samples (white arrows, b). After pre-treatment with pamidronate followed
by transplantation, mandible BMSCs formed structurally less-organized osteoid-like bone with
fewer cells and loss of osteoblastic rimming (dark arrows, d) but iliac crest BMSCs formed a
more fibrocellular bone matrix with cell-lined surface. Representative immunohistochemical
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staining with rabbit anti-human osteopontin (mandible control shown) confirms that bone
formed by transplanted BMSCs were of human origin and not mice (e). Semi-quantitative
analysis of in vivo bone showed that BMSCs pre-treated with pamidronate recovered from
effects of pamidronate to form appreciable bone although not significantly higher than their
respective controls (f). Higher quantitative bone by both control and pamidronate-treated
mandible BMSCs further confirm their better ectopic bone-forming capacity relative to iliac
crest BMSCs. (Data presented are representative histology sections and mean of n = 6 subjects).
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